Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultra long acting basal insulin - Gan & Lee Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ultra long acting basal insulin - Gan & Lee Pharmaceuticals

Alternative Names: GZR-33

Latest Information Update: 26 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gan&Lee Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetes mellitus

Most Recent Events

  • 28 Jun 2024 Phase-II clinical trials in Diabetes mellitus in China (Parenteral) (NCT06558708)
  • 21 Jun 2024 Pharmacodynamics and pharmacokinetic data from a preclinical trial in Diabetes mellitus presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)
  • 03 Feb 2024 Gan and Lee Pharmaceuticals completes the phase I trial in Diabetes mellitus (In volunteers) in China (SC) (NCT06556641)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top